BioUcenta

BioUcenta is a UK-based biotechnology company specializing in the development of novel cancer therapeutics targeting the FXYD3 protein. A spin-out from Imperial College London, the company focuses on hard-to-treat solid tumors, with a primary emphasis on pancreatic ductal adenocarcinoma (PDAC). Their lead candidate, BU-01, is a monoclonal antibody designed to inhibit the FXYD3 ion channel regulator, which is overexpressed in several aggressive cancers. By targeting this specific protein, BioUcenta aims to disrupt tumor growth and improve patient outcomes in oncology. The company's research is based on decades of ion channel research conducted at Imperial College. BioUcenta is currently advancing its lead program through pre-clinical development toward clinical trials.